Supplementary figure 1 | gating strategy for selecting CD3+ T cells from DC-CIK cells
Supplementary Figure 2

Supplementary figure 2 | Annexin V-APC/7-AAD apoptosis assay and cell viability assay with CCK8 kit. a The apoptosis rates of CD3+T cells from DC-CIK cells which were treated with mock (PBS), ERK inhibitor (100 nM/L), AKT inhibitor (1.0 μM/L) or pembrolizumab (500 μg/ml) for 48h. b Statistical histogram of (a). c, d, e the viability of DC-CIK cells when treated with different concentrations of ERK inhibitor (0, 50, 100, 150 nM/L) (c), AKT inhibitor (0, 250, 500, 1000 nM/L) (d) or pembrolizumab (0, 125, 250, 500 μg/ml) (e) for 72h. Representative results from three independent experiments are shown. “ns” indicated as no statistical significance.